To review the recent advances and current controversies in patients with Zollinger-Ellison syndrome (ZES).
INTRODUCTION
In the last few years, there have been a number of advances regarding the pathogenesis, management, and specific treatment of gastrinomas causing the Zollinger-Ellison syndrome (ZES), as well as other pancreatic neuroendocrine tumors (pNETs), and a number of areas of controversy. In this article, we will review these, concentrating on articles within the last 2-3 years [ ] and treatment of advanced disease [cytoreduction, liver-directed treatments (embolization, chemoembolization, and radioembolization), biotherapies (somatostatin analogues and interferon), peptideradio-receptor therapy (PRRT), chemotherapy, molecular-targeted medical therapies with mTor-inhibitors (everolimus) and tyrosine-kinase inhibitors (sunitinib), and liver transplantation] [6 && , [7] [8] [9] [10] [11] . Furthermore, a number of consensus guidelines covering all the aspects of management of pNETs, including gastrinomas, have recently been published [8, 9, 12, 13 of effective antisecretory medications [proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2Rs)], this form of presentation has markedly decreased [14, 16, 19 & ,20], however, a number of recent reports still describe cases presenting with these complications [21] [22] [23] . This should not be too surprising, because the delay in diagnosis of ZES remains 6-9 years and has not changed, despite more than 3600 articles on ZES and the widespread availability of gastrin radioimmunoassays [16, 20] . At present, most ZES patients present with pain due to a typical duodenal ulcer or gastroesophageal reflux (GERD), but up to 75% manifest diarrhea and this may be the sole presenting symptom in 3-10% [16,24 & ], as well illustrated in a recent case record in the New England J Medicine [24 & ].
In 20-25% of ZES patients, concomitant multiple-endocrine-neoplasia-type 1 (MEN1) is present [9, 14, 25, 26] . MEN1 is an autosomal-dominant syndrome due to defects in the MEN1 gene (chromosome 11q13), resulting in alterations of a 610-amino acid nuclear protein, menin [27] . These patients characteristically develop hyperparathyroidism (90-99%), pNETs (80-100%), and pituitary adenomas (50-65%), with the most common, functional pNET syndromes being ZES (mean 54% and range 20-61%) and insulinoma (7-31%) [27] . Although most patients initially present with hyperparathyroidism, a proportion can present with ZES, and the hyperparathyroidism can be mild and difficult to detect [25] [26] [27] [28] . Two recent articles [21, 23] report that these patients can also present with PUD complications (bleeding and perforation). Although this is now a less common form of presentation with the availability of antisecretory drugs, nevertheless it is not uncommon or surprising because the delay in diagnosis in MEN1 patients, in whom ZES should be potentially suspected in all, is still 5 years [25, 27] . Recent studies show that ZES presents 10 years earlier in MEN1 patients (mean 33.2 years), and that the hyperparathyroidism can affect the activity of the ZES, and can even mask the ZES's presence if adequately controlled [16, 25, 29, 30] , therefore, it is important that all patients with MEN1 be assessed for ZES.
Although ZES occurs in most cases as a separate distinct syndrome, it is important to remember that it is one of the pNET syndromes, most frequently reported in association with other functional pNET syndromes [16, 25] such as Cushing's syndrome, carcinoid syndrome, insulinoma, and parathyroid hormone-related protein secreting tumors. In recent articles, these include: Cushing's syndrome, especially in patients with advanced metastatic gastrinoma (ectopic Cushing's) or in patients with MEN1 (pituitary Cushing's) [25, 27, [31] [32] [33] [34] ; insulinomas (especially in MEN1 patients) [25, 35] ;or parathormone-related peptide secreting tumors [36] .
Disease, classification, and molecular pathogenesis
In the original description of ZES [37] and in most early studies, it was thought that the gastrinoma was pancreatic in location (nonb-cell tumor) [18, 37] , however, recent surgical series [14, [38] [39] [40] [41] show 40-90% of gastrinomas are duodenal, in both patients with/without MEN1. This change is because of the fact that duodenal gastrinomas are frequently small (<1 cm), not seen on imaging, and thus were easily missed in the early studies, and are still missed at surgery, if a routine duodenotomy is not performed [14, 38, 39, 42, 43] In early studies, 60-90% of gastrinomas were associated with metastases [14, 39, 41] . Surgical studies demonstrate that 30-70% of patients with duodenal or pancreatic gastrinomas have lymph node metastases. Liver metastases, however, are
KEY POINTS
There are new advances, as well as controversies, in the diagnosis and management of patients with ZES.
The widespread use of PPIs, which itself induces hypergastrinemia, is making the diagnosis of ZES more difficult to accomplish.
Although the diagnosis of ZES requires the measurement of fasting serum gastrin, new data suggest that many current commercial gastrin assays are not reliable.
The surgical treatment of patients with ZES and MEN1 remains controversial.
Novel modalities to treat advanced ZES include cytoreductive surgery, liver-directed therapies (embolization, chemoembolization, and radioembolization), chemotherapy, biotherapy (somatostatin analogues and interferon), moleculardirected therapies (everolimus and sunitinib), liver transplantation, and peptide-radioreceptor therapy, a number of which have recently been evaluated by prospective, phase 3 double-blind studies in patients with advanced NETs. much more frequent in patients with pancreatic gastrinomas [41, 50] . At present, the molecular basis for this difference is unknown.
Recently, it has been proposed that gastrinomas, as well as all pNETs and carcinoid tumors, should be classified as NETs [ ,56]. The exact cell of origin of gastrinomas, remains a subject of controversy with some suggesting that pancreatic gastrinomas may originate from islet and/or duct cells [59, 60] . In the case of duodenal gastrinomas in patients with MEN1, but not with sporadic duodenal gastrinomas, studies suggest their pathogenesis involves increasing degrees of proliferation of duodenal G-cells concomitant with loss-of-heterozygosity at the MEN1 locus (11q13) in the G-cell [59, 61] .
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF ZOLLINGER-ELLISON SYNDROME
The diagnosis of ZES is not straight forward and is becoming both controversial as well as more difficult. It is becoming more controversial because of the difficulty diagnosing of ZES with the widespread use of PPIs and the contrasting approaches proposed in different articles/guidelines, recently [ . Each of these issues will be briefly discussed below.
The first study usually performed when ZES is suspected is a fasting serum gastrin concentration [62 && ,69] , because in more than 99% of ZES patients, fasting hypergastrinemia is present, except in uncommon, special circumstances (previous gastrinoma resection and MEN1/ZES postparathyroidectomy) [29,62 && ,71,72] . Alarmingly, a recent study [70 && ] reported that seven of 12 commercial gastrin assay kits inaccurately measured fasting serum/plasma gastrin concentrations either overestimating or underestimating the true value, because these assays used antibodies with inappropriate specificity, that were insufficiently validated. These assays could result in ZES being unduly suspected or result in the diagnosis being missed [62 && ,70 && ]. Furthermore, secretin (or glucagon in countries where secretin is not available) [73] , and to a lesser extent, calcium gastrin-provocative tests are needed in a subset of patients with ZES, to firmly establish the diagnosis [62 && ,74] , and a positive response (>120 pg/ml increase¼secretin, 395 pg/ml¼calcium) can only be determined using an accurate gastrin assay [74] . Therefore, without a reliable gastrin assay it is not possible to be certain whether ZES is present or not. To circumvent these problems, it is recommended that either one of the five reliable gastrin assays listed in this article be used or a group well versed in diagnosing ZES in your area be contacted to ascertain which gastrin assay in your area is reliable.
Hypergastrinemia can either be physiological (due to hypo-achlorhydria/achlorhydria) or inappropriate due to a disease process such as ZES, resulting in the inappropriate release of gastrin, despite the presence of gastric acidity [69, 75] . Physiological hypergastrinemia is the most common cause of fasting hypergastrinemia, and frequently observed in patients with chronic atrophic gastritis/pernicious anemia (hypochlorhydria), chronic helicobacter infection of the oxyntic mucosa (hypochlorhydria), PPI use (hypochlorhydria), and renal failure [62 && ,65, 66, 69, 75] . This group of patients is much more frequent than ZES, and therefore must be distinguished from the patients with ZES [62 && ,65, 66, 69] . Unfortunately, in patients with chronic atrophic gastritis/pernicious anemia, there is no level of hypergastrinemia alone that can separate these patients from patients with ZES. In most recent reviews as well as all recent guidelines [1 & ,12,13 && ,62 && ,63 && ,66,69], it is proposed that the only certain approach to identify most patients with hypergastrinemia as possibly having ZES, is to assess the gastric acidity by measuring the Hþ ion concentration (pH). In a review of 1219 patients with ZES [76] , it is reported that 100% of patients without previous gastric acid-reducing surgery and off antisecretory medications had a gastric pH less than 2. This approach, however, is somewhat controversial because this approach is not without potential risk, because ZES patients can quickly develop acid-peptic complications when taken off PPIs for the recommended 1 week [62 && ,64 && ,69]. Furthermore, because PPIs have a long duration of action (up to 1 week), to be certain uninhibited gastric acidity returns, it is recommended that PPIs be stopped for at least 1 week 66, 69] . A recent study [64 && ] reports two patients with suspected ZES (later proven) who developed severe complications of PUD when the PPIs were stopped (esophageal stricture and intestinal perforation), and it is proposed that PPI treatment be maintained and the diagnosis of ZES established while the patient continues to take PPIs or a reduced dose of PPIs. Unfortunately, as pointed out in two recent commentaries [62 && ,63 && ], this is not possible in most cases, because many patients with ZES continue to have profound acidinhibition with low doses of PPIs; there is no clinical feature that unequivocally establishes the diagnosis of ZES; there is no absolute level of gastrin or any tumor marker (chromogranin A, etc.) that distinguishes ZES; pNETs are frequently not seen on imaging studies, and even the establishment of a pNET containing gastrin does not unequivocally establish the diagnosis of ZES [62 && ,63 && ]. Lastly, a positive secretin-provocative test (120-pg/ml increase) which is frequently used to establish the diagnosis of ZES in questionable cases and has a sensitivity of 94% and specificity of 100% [74] , may not give reliable results while patients are taking PPIs, because PPI's use can lead to a false-positive secretin test [77] . Because of these potential difficulties in making the diagnosis of ZES and withdrawing PPIs, it is recommended that the best approach is to consider referring the patient to a group well versed in establishing the diagnosis of ZES [ ]. Long-term PPI treatment in ZES has proven well tolerated with very few side-effects (<0.1%) causing treatment to be stopped [19 & ,82-87] . The long-term effects of PPI-induced hypo-achlorhydria/achlorhydria include a potential concern related to possible nutrient malabsorption [ Prolonged hypergastrinemia in animals and humans causes proliferation of gastric mucosal enterochromaffin-like (ECL) which rarely progresses to carcinoid tumors in human cells (ECL cells), and in numerous animal models of chronic hypergastrinemia, with time, gastric carcinoids (ECLomas) can develop, some of which are malignant [83, 88, 89] . It has been proposed that gastric carcinoids develop through a sequence involving increasing degrees of ECL-cell hyperplasia (diffuse, linear, micronodular, and dysplasia) [19 & ,83] . PPIs increase the incidence of gastric carcinoids in animals, but not in humans [90] . However, hypergastrinemia alone in humans appears to rarely cause a gastric carcinoid, at least up to 10 years, because these rarely occur in patients with sporadic ZES (non-MEN1) [19 & ,83,88 ]. In contrast, gastric carcinoids develop in 23% of patients with ZES/MEN1 [89] and are not infrequent in chronic atrophic gastritis/pernicious anemia [90] , suggesting an accompanying defect may be needed in humans, such as loss of the MEN1 gene or the presence of chronic atrophic gastritis, at least for the short-term development of gastric carcinoids (<10 years) [ 14, 15, 92] . Numerous imaging modalities are used for preoperative assessment or serial assessment of tumor location/extent including: cross-sectional imaging studies [computed tomography (CT) scanning, magnetic resonance imaging (MRI), and ultrasound]; selective angiography; somatostatin-receptor scintigraphy (SRS) using 111Indium-labeleled somatostatin analogues or 68Gallium-labeled somatostatin analogues with positron emission tomographic imaging (PET scanning); endoscopic ultrasound (EUS) and assessment of gastrin hormonal gradients either assessed transhepatically in portal venous drainage or in hepatic veins after selective intra-arterial secretin stimulation [5 & ,12,14,15,93-95] . At the time of surgical exploration, the use of intraoperative ultrasound, transillumination of the duodenum, and performance of a duodenotomy to localize small duodenal primaries is recommended [14, 96, 97] .
Cross-sectional imaging with CT or MRI with contrast enhancement (CT and MRI) remains the most widely used initial imaging study in ZES patients, because of its widespread availability, however, their detection rate is size dependent missing many lesions less than 1 cm [5 & ,15,43,92,98,99] . SRS is the most sensitive modality for assessing the extent of the disease and is valuable in ZES, as in other pNETs, for detecting liver/distant metastases, as well as the primary tumor [15,99-101,102 & ].
In the United States, SRS is performed using 111Indium-labeleled somatostatin analogues with single photon emission computed tomography (SPECT) imaging. Studies in Europe, and in a few centers in the United States, demonstrate that 68Gallium-labeled somatostatin analogues with PET scanning, is more sensitive, and likely will become the procedure of choice in the future
Cross-sectional imaging detects 30-50% of primary gastrinomas less than 1-2 cm, whereas SRS with 111Indium-labeleled somatostatin analogues with SPECT imaging detects 60-70%. For hepatic metastases, cross-sectional imaging detects hepatic metastases in a patient with proven hepatic metastases in 70-80%, whereas SRS detects them in 85-95% [15, 99, 100, 103] . EUS is useful for localizing pancreatic gastrinomas, but misses 50% of duodenal gastrinomas, and thus is of limited value in ZES [104] . Assessment of gastrin gradients is now rarely used in ZES patients.
SURGICAL TREATMENT OF LOCALIZED GASTRINOMA
Recent guidelines and other studies agree that in patients with sporadic ZES (without MEN1/ZES), surgery for cure should be attempted if there is not an accompanying illness limiting life expectancy or increasing surgical risk [3 & ,12,13 && ,14,15]. The immediate postoperative cure rate in the National Institutes of Health prospective studies is 50-60%, and the long-term cure rate is 35-40% [38, 97, 105] . Surgical resection in ZES patients decreases the rate of development of hepatic metastases and increases survival [32, 50, 106, 107] . Even in ZES patients with negative imaging, a recent study reports an experienced surgeon will find a gastrinoma in 98% and 50% will be cured [108 && ]. In this study [108 && ], the patients with negative imaging had a mean delay of 8.9 years from onset of ZES to surgery which was significantly longer than patients with positive imaging, and 7% had liver metastases at the time of surgery, raising the possibility of long delays contributing to the development of liver metastases. Although it is well established that the presence/development of liver metastases is an important prognostic factor in patients with ZES, the routine resection of lymph nodes is controversial, not only because of the controversy over whether lymph-node primary gastrinomas exist [109] [110] [111] , but also because the importance of identifying lymph node metastases is controversial, with some studies showing these have prognostic significance and others not [ ] was significantly lower. In one study [112 & ], the time to the development of liver metastases was significantly reduced in patients with lymph node metastases, and in a large subgroup of patients with gastrinomas with longer follow-up, the presence of lymph node metastases was associated with decreased disease-related survival and the decrease was a function of the number of lymph nodes involved. Each of these studies concluded that lymphadenectomy should be routinely performed in patients with gastrinomas and other pNETs, and that this not only has prognostic value, but it may also prolong recurrences and increase survival [112 & ,113 & ,114,115] . Another area of increasing surgical controversy is the role for laparoscopic surgery in patients with ZES. Laparoscopic resection is increasingly being used in patients with pNETs, especially in patients with insulinomas or in some cases with nonfunctional pNETs, which are localized by imaging [116, 117] . A small number of patients with ZES have undergone laparoscopic resection [116] [117] [118] with favorable outcomes. Because of the need for complete exploration of the abdomen, especially of the gastrinoma triangle area (duodenum/pancreatic head area), routine lymphadenectomy, and routine duodenotomy combined with a Kocher maneuver, it has been recommended that the standard operation in ZES patients not be performed laparoscopically. However, there may be a place for laparoscopic surgery in selected cases such as patients with localized distal pancreatic gastrinoma. The timing, type of operation, and place of routine surgical exploration in patients with MEN1/ZES remains controversial. This occurred because numerous studies demonstrate that these patients usually (>85%) have duodenal gastrinomas, in addition to pancreatic pNETs which are primarily nonfunctional pNETs (<15% gastrinomas), and the duodenal gastrinomas are invariably multiple, often small (<0.5 cm), and in 40-60% of cases associated with lymph node metastases [14, 40, 105, 119] . Consequently, enucleation or local resection rarely leads to long-term cure. Some authors suggest that cure can only be achieved by performing a pancreaticoduodenectomy (Whipple/or related operation) [14, 27, 40, 119] . MEN1/ZES patients with small (<1.5-2 cm) pancreatic pNETs have excellent prognoses (survival up to 90-100% 15 years without surgery), as well as MEN1/ZES patients with small duodenal gastrinomas. Some propose that all patients with MEN1/ZES undergo surgical exploration and resection/enucleation of any pNET; others that only selected patients with pNETs more than 2 cm undergo exploration and still others propose aggressive resection with pancreaticoduodenotomy, if needed, be considered [14, 27, 104, 120, 121] . Still others recommend routine pancreaticoduodenectomy in an attempt at cure. Each approach has its advocates, but there are no prospective studies to provide guidance. This confusion partially exists because the current natural history of patients with MEN1/ZES or MEN1/pNETs is unclear [9] . Recent ENETs and North American Neuroendocrine Tumor Network guidelines [12,13 && ] recommend surgery for possible cure not be undertaken routinely but be reserved for ZES patients with more than 2-cm lesions and 
TREATMENT OF GASTRINOMA PATIENTS WITH ADVANCED METASTATIC DISEASE
It should be kept in mind that most gastrinomas (60-90%) are malignant and most are not cured by surgery. Treatment directed at the metastatic gastrinoma in patients with advanced disease, as with other advanced pNETs, is becoming increasingly important, now that the hormone-excess state can be effectively managed in most cases [6 && ,14,122 && ]. Only 40% of sporadic ZES patients are cured and almost none with MEN1. The presence of liver metastases is one of the most important prognostic factors for survival in patients with ZES, with survival decreasing with increasing extent of hepatic metastases [15, 32, 50] . The 10-year survival in patients with diffuse metastatic gastrinoma in the liver is 15-25% [6 && , 32, 50] . There are only a limited number of studies specifically addressing the treatment of ZES patients with advanced disease, and most data come from series with patients with all the different pNETs, gastrinomas included. This occurs because most centers have limited numbers of these patients, and more importantly, because the antitumor treatments of advanced pNETs are similar for all the different pNETs, with differences occurring primarily in the treatment of the different hormone-excess states. Recently, a number of guidelines became available covering antitumor treatment in patients with advanced, metastatic disease due to pNETs [6 && ,12,13 && ,122 && ,123,124], as well as a number of recent reviews that cover all aspects of these treatments. These include reviews of the use of cytoreductive surgery ]. Because this area is well covered in recent reviews and the findings/approaches are not specific for ZES, but used for all pNETs, this area will be only briefly discussed.
Cytoreductive surgery is recommended for ZES patients in which at least 90% of visible metastatic tumor is considered resectable [6 && ,122 && ,125,126], however, only 5-15% of patients with metastatic ZES fall into this category. It has been used in small numbers of patients with gastrinomas [14, 139] . Whether this approach prolongs survival, however, is not known because no controlled-studies exist. A recent study [140] in patients with ZES/pNETs demonstrates that many patients with advanced disease with vascular abutment/invasion on preoperative imaging studies may benefit from surgery, because in contrast to those with adenocarcinoma, the pNETs can still be resected, with vascular reconstruction needed only in a small subset.
Chemotherapy (streptozotocin in combination with 5-fluorouracil and/or doxorubicin) remains an important treatment in patients with metastatic gastrinomas [14, 129, 141] . It produces a response rate of 20-45%, but no long-term cures, and the drugs have considerable side-effects, especially nephrotoxicity. Recently, in 30 patients with different metastatic pNETs, the combination of temozolomide/capecitabine had a partial response rate of 70%, with a median progression-free survival of 92% [142] . Whether this high response rate will be corroborated by other studies and also seen in patients with metastatic gastrinomas is unclear at present.
Liver-directed therapies (embolization, chemoembolization, radioembolization, and radio-frequency ablation) are used in patients with hepatic predominant disease, but are used less frequently in ZES than in other metastatic pNETs, because in ZES, the hormone-excess state can be well controlled medically, whereas in other functional pNETs, refractory states to drugs may develop, necessitating this approach 126, 130] . Whether any of these liver-directed therapies prolong life or whether one is better than the other is not known, which is the preferred one or when exactly should these be used, has not been addressed in any prospective study.
Biotherapy with somatostatin analogues and/or interferon for their antiproliferative effects in patients with advanced metastatic gastrinomas has been used [143, 144] In the RAD001 in advanced neuroendocrine tumors (RADIANT)-3 study [135 && ], involving 410 patients with advanced, progressive pNETs, everolimus demonstrated a significant improvement in progression-free survival (11 vs 6 months, P < 0.0001) and no difference in overall-survival, likely because of the cross-over of patients. In the sunitinib study [136 && ], involving 171 patients with progressive, advanced pNETs, sunitinib treatment resulted in a doubling of progression-free survival (11.4 vs 5.5 months, P < 0.001), an increase in the rate of objective tumor-response (9 vs 0%, P ¼ 0.007), and an increase in the overall survival. Both everolimus and sunitinib are not without side-effects with everolimus causing a two-fold and sunitinib a three-fold increase in side-effects compared with controls [6 && ,135 && ,136 && ,137], however most side-effects were grade 1/2 and could be controlled with either dose reduction or treatment cessation. The ENETs 2012 guidelines [122 && ] conclude that everolimus or sunitinib represent novel therapeutic options in patients with surgically non-resectable pNETs with progression following chemotherapy, and should be considered first-line in only selected cases. In contrast, in the United States, the NCCN guidelines list the use of everolimus/sunitinib as a possible firstline treatment for unresectable well differentiated pNETs [6 && ,150]. PRRT using radiolabeled somatostatin analogues is based on the finding that most pNETs (60-100%) overexpress somatostatin receptors, and this allows targeting of cytotoxic-radiolabeled compounds 151, 152] complete tumor regression was seen in 2%, partial regression in 28% , minor regression in 16%, and stabilization in 35%. In 310 patients followed [152] , the median duration of objective responses was 46 months, and median disease-related survival was not reached (>48 months). PRRT using either 90 Yttrium-labeled or 177 Lutetium-labeled somatostatin analogues has been used in a number of patients with ZES with advanced tumors, with partial tumor response occurring in more than 40% and in fact, the response rate is one of the highest of all patients treated with metastatic NETs, however, the recurrence rate is also high [152, 153] . Severe side-effects are uncommon with hematological toxicity in 15%, with 0.8% developing 151, 152] . This treatment is not approved for routine use in the United States or Europe, however, this approach appears promising and is now undergoing, in both the United States and Europe, a double-blind, prospective study in patients with advanced gastrointestinal-ileal carcinoids, to prospectively evaluate its efficacy/toxicity.
CONCLUSION
There have been recently numerous advances in the management/treatment/understanding of ZES as well as a number of areas of controversy, each of which are reviewed here. 
